Viridian Therapeutics: Strategic Positioning and First-Mover Advantage in the TED Market
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...
Viridian Therapeutics: Promising Prospects and Strategic Positioning Fuel Buy Rating
Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami ...
Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have received a consensus recommendation of “Moderate ...
Investing5d
Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics, Inc. (VRDN) today announced that Stephen Mahoney has been appointed the company’s President and Chief Executive Officer, and a member of the Board of... ByInvesting.com ...
Morningstar3d
Viridian Therapeutics Inc VRDN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance5d
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized ...
Yahoo Finance4d
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI, January 07, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 43 rd Annual J.P ...